Evaluation and Management of Primary Aldosteronism

• Parisien-La Salle, Stéfanie ^[1] ; Vaidya, Anand ^[2]
  1. [1] University of Montreal

     University of Montreal

     Canadá

     
  2. [2] Harvard Medical School

     Harvard Medical School

     City of Boston, Estados Unidos

     
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 55, Nº. 2, 2026, págs. 271-284
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • In summary, PA is now recognized as a common cause of hypertension in which targeted therapy can substantially mitigate the excess cardiovascular and renal risk associated with aldosterone excess. New guidelines streamline diagnosis by recommending a pragmatic approach that centers around identifying renin-independent aldosterone production without excessive requirements for medication changes or dynamic testing. Steroidomics, functional nuclear imaging, along with emerging therapies including